The verdict
Our read at a glance.
Whether macimorelin is understood as an approved oral ghrelin-receptor agonist used as a one-time growth-hormone stimulation test for adult growth-hormone deficiency, rather than a growth-hormone-boosting or anti-aging treatment.
- The signal
- A head-to-head validation trial compared the oral macimorelin test against the insulin tolerance test, the long-standing reference for diagnosing adult growth-hormone deficiency, and found good agreement with high sensitivity and specificity and reproducible results, in a much simpler and safer oral protocol. That evidence is what earned its approval.
- The unknown
- The open questions are practical: growth-hormone responses are blunted in people with obesity, which complicates any stimulation test and its cutoff; strong drug interactions can cause false results; and performance in borderline or partial deficiency is less clean. Its role as a diagnostic is settled, and there is no role as a treatment.
- Our read
- The rare oral ghrelin-receptor agonist that actually won approval, but only as a one-time test, not a treatment. Macimorelin reliably provokes a growth-hormone surge to show whether the pituitary can still make growth hormone, giving a safer oral alternative to the insulin tolerance test. Read it as a diagnostic, and as the telling contrast to the ghrelin-receptor peptides (MK-677, ipamorelin) sold for chronic boosting: same receptor, but the approved use is a single diagnostic dose.
The mechanism
How it works.
The body's own hunger hormone, ghrelin, also tells the pituitary to release growth hormone by switching on a receptor on the gland's growth-hormone-making cells. Macimorelin is a small, orally active molecule built to act like ghrelin at that receptor. Swallowed as a single weight-based dose after fasting, it triggers a burst of growth hormone in someone whose pituitary is healthy; in adult growth-hormone deficiency the gland cannot mount that surge, so the blood growth-hormone level stays low. By measuring growth hormone in the blood over the 90 minutes after the drink, clinicians can tell a normal response from a deficient one. Because it works through the same ghrelin receptor that the popular growth-hormone-secretagogue peptides target, it is chemically in their family, but it is used once, to measure, not repeatedly to boost.
Safety & regulatory boundary
The consequential part.
Macimorelin modestly prolongs the heart's QT interval, so other QT-prolonging drugs are avoided around the test, and strong CYP3A4 inducers lower its levels and can cause a falsely low (false-positive) growth-hormone result, so they are stopped beforehand. It is an oral diagnostic agent given as a single dose under medical supervision, not a medicine taken over time. Macrilen is not the same as research-labeled macimorelin or the unapproved ghrelin-receptor peptides (MK-677, ipamorelin, GHRP) marketed for muscle or anti-aging, and its approval covers a one-time test only, not growth-hormone or IGF-1 enhancement.
What's next
What we're watching.
Real-world accuracy across body-weight ranges and in partial deficiency, drug-interaction false-positive reporting, and whether the oral test fully replaces the insulin tolerance test in practice.
Context
Why this is discussed.
People in the peptide world chase oral ghrelin-receptor agonists like MK-677 to push up growth hormone. Macimorelin is the one oral ghrelin-receptor agonist that actually earned FDA approval, but tellingly only as a diagnostic test used a single time, which is a clear-eyed contrast to how the same receptor is marketed for muscle and anti-aging.
The evidence base
19 cited references.
Regulatory & labels2
Novo Nordisk (FDA label) · 2021
Aeterna Zentaris GmbH (FDA label) · 2026
Registered trials6
ClinicalTrials.gov · PHASE3 · COMPLETED · 2021-11-16
ClinicalTrials.gov · PHASE2 · COMPLETED · 2012-05
ClinicalTrials.gov · NA · COMPLETED · 2019-03-07
ClinicalTrials.gov · PHASE3 · COMPLETED · 2007-06
ClinicalTrials.gov · PHASE3 · COMPLETED · 2015-12-03
ClinicalTrials.gov · PHASE1 · COMPLETED · 2005-11
Indexed literature (PubMed)11
Yuen KCJ et al. · Endocr Connect · 2023
Agrawal V et al. · Expert Rev Mol Diagn · 2014
Arlien-Søborg MC et al. · Pituitary · 2025
Henry RK · touchREV Endocrinol · 2022
Wang RL et al. · Acta Pharmacol Sin · 2025
Garcia JM et al. · J Clin Endocrinol Metab · 2018
Garcia JM et al. · Endocr Connect · 2021
Feingold KR et al. · 2000
Csákváry V et al. · Horm Res Paediatr · 2021
Gabreanu GR · Discoveries (Craiova) · 2018
Tritos NA · Best Pract Res Clin Endocrinol Metab · 2021
Keep reading